Affiliation:
1. 1Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract
Summary
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival.
See related article by Tolmeijer et al., p. 2835
Funder
National Cancer Institute
Publisher
American Association for Cancer Research (AACR)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献